

OPIOID ANALGESICS

TRENDS, GUIDELINES, RESOURCES

Prepared for:
International Association for the Study of Pain
10th World Congress on Pain
San Diego, CA
August 17 – 22, 2002

Prepared by:
Pain & Policy Studies Group
WHO Collaborating Center for Policy and
Communications in Cancer Care
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin
USA
www.medsch.wisc.edu/painpolicy
joranson@wisc.edu



ABOUT THE PAIN & POLICY STUDIES GROUP

The Pain & Policy Studies Group (PPSG) mission is to study and educate about the need for “balance” in international, national and state pain policies: to ensure adequate availability of opioid analgesics and their appropriate medical use for patient care while addressing diversion and abuse. The PPSG is designated the World Health Organization (WHO) Collaborating Center for Policy and Communications in Cancer Care. Much of the PPSG’s work, including new WHO Guidelines that are discussed later in this document, are available on the PPSG website at www.medsch.wisc.edu/painpolicy.

The PPSG supports a global communications program to improve access to information about pain relief, palliative care, and pain policy, and publishes a WHO newsletter *Cancer Pain Release* (www.whocancerpain.wisc.edu).

RELEVANT WEBSITES

- Pain & Policy Studies Group/World Health Organization Collaborating Center for Policy and Communications in Cancer Care
www.medsch.wisc.edu/painpolicy
- WHO Newsletter *Cancer Pain Release*
www.whocancerpain.wisc.edu
- World Health Organization (WHO)
www.who.int/home-page/
- International Narcotics Control Board
www.incb.org/

TABLE OF CONTENTS


Global consumption trends of Fentanyl, Methadone, Morphine, Oxycodone, Pethidine	1
Global consumption of morphine, 1999 (mg/capita).....	2
Achieving Balance in National Opioids Control Policy, Guidelines for Assessment.....	4
Bibliography	10

CITATION FOR THIS MONOGRAPH

Pain & Policy Studies Group. *Opioid Analgesics: Trends, Guidelines, Resources*. University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; Madison, Wisconsin, USA. Prepared for: International Association for the Study of Pain, 10th World Congress on Pain; San Diego, California: 17-22 August 2002 (Monograph).

Global Consumption of Opioid Analgesics

1981 - 2000



Graph: Per Capita Consumption of Morphine, 1999




Table: Per Capita Consumption of Morphine, 1999

Falkland Islands	74.0000	Bulgaria	2.0328	Brunei Darussalam	0.2447
Denmark	70.7567	Chile	1.9670	Mauritius	0.2240
Australia	57.0705	Jamaica	1.9531	Iran (Islamic Republic of)	0.2025
Canada	52.0475	Barbados	1.7903	Paraguay	0.2001
Iceland	50.2545	Brazil	1.7769	Turks and Caicos Islands	0.1875
New Zealand	37.6505	Georgia	1.5566	Kuwait	0.1846
Sweden	37.2499	Seychelles	1.4750	Peru	0.1741
Austria	36.3185	Argentina	1.4729	Egypt	0.1625
France	31.7967	Belarus	1.3208	Antigua and Barbuda	0.1493
Norway	29.7250	Colombia	1.2733	Mexico	0.1437
United States of America	28.9582	Republic of Korea	1.1849	Botswana	0.1353
Switzerland	25.7126	Bahamas	1.1595	Mongolia	0.1282
United Kingdom	19.9868	Lebanon	1.0343	Jordan	0.1223
Kazakhstan	18.3779	Tunisia	1.0121	Morocco	0.1158
Germany	16.8477	Singapore	1.0110	China	0.1102
Ireland	16.5869	Aruba	0.9894	Syrian Arab Republic	0.1059
Israel	14.5262	Latvia	0.9807	Nicaragua	0.0972
Belgium	11.3191	Netherlands Antilles	0.9488	Zambia	0.0961
Netherlands	9.9081	Grenada	0.8602	India	0.0884
Slovenia	9.0669	Malaysia	0.8440	Yugoslavia	0.0715
Luxembourg	8.4149	Fiji	0.7680	Wallis and Futuna Islands	0.0714
Slovakia	7.6669	Croatia	0.7398	Kyrgyzstan	0.0711
New Caledonia	7.6553	Greece	0.6899	Iraq	0.0696
Finland	7.5398	Saint Vincent & the Grenadines	0.6696	Myanmar	0.0521
Spain	7.2408	Bahrain	0.6261	Uzbekistan	0.0519
Hungary	7.1883	Macao	0.6244	Rwanda	0.0510
Japan	6.7843	Albania	0.6200	Dominica	0.0423
Poland	6.5055	Oman	0.5557	Algeria	0.0392
Namibia	5.6814	Saint Kitts and Nevis	0.5385	Honduras	0.0377
Czech Republic	5.4825	Russian Federation	0.5191	Bolivia	0.0232
Republic of Palau	4.7895	Armenia	0.5036	Pakistan	0.0223
Estonia	3.9610	Republic of Moldova	0.4306	Vanuatu	0.0215
Cayman Islands	3.8108	Panama	0.4279	Nepal	0.0150
Hong Kong SAR	3.5837	Sierra Leone	0.4240	Libyan Arab Jamahiriya	0.0132
Malta	3.3990	Saudi Arabia	0.4169	Guatemala	0.0087
South Africa	3.3620	United Arab Emirates	0.3824	Uganda	0.0083
Form.Yug. Rep.of Macedonia	3.2700	Dominican Republic	0.3434	Guyana	0.0082
Andorra	3.0933	Turkey	0.3407	Cape Verde	0.0072
Djibouti	3.0843	Cook Islands	0.3158	Cambodia	0.0056
Portugal	2.6719	Sri Lanka	0.3064	Indonesia	0.0054
Cuba	2.5746	Suriname	0.2892	Eritrea	0.0051
Italy	2.3543	Thailand	0.2868	Niger	0.0048
Cyprus	2.2935	Tonga	0.2857	Madagascar	0.0045
Costa Rica	2.2502	Samoa	0.2485	Dem. Rep. of the Congo	0.0033
Lithuania	2.1614	Qatar	0.2479	United Republic of Tanzania	0.0014
				Nigeria	0.0007

Source: International Narcotics Control Board, United Nations "Demographic Yearbook," 1999

WHO/EDM/QSM/2000.4
ENGLISH ONLY
DISTRIBUTION: GENERAL

NARCOTIC & PSYCHOTROPIC DRUGS

**ACHIEVING BALANCE
IN NATIONAL
OPIOIDS
CONTROL POLICY**

GUIDELINES FOR ASSESSMENT



WORLD HEALTH ORGANIZATION

EXECUTIVE SUMMARY

The World Health Organization (WHO) has determined that the inadequate management of pain due to cancer is a serious public health problem in the world. Worldwide, there are 10 million new cases of cancer and 6 million deaths annually from this noncommunicable disease (1). Twenty years from now, the global burden of cancer will double. The incidence of cancer, presently greatest in developed countries, will shift to developing countries, reflecting better prevention strategies in the developed world. The WHO Programme on Cancer Control has estimated that by the year 2020, approximately 70% of the annual 20 million new cancer cases will occur in developing countries (1), where most patients are diagnosed when the disease is already in the late stages. Pain is prevalent in cancer, but especially in the late stages, near the end of life.

Tragically, cancer pain frequently goes untreated; when it is treated, relief is often inadequate. Yet, the WHO has demonstrated that most, if not all, pain due to cancer *could* be relieved if we implemented *existing* medical knowledge and treatments. There is a treatment gap: it is the difference between what can be done, and what *is* done about cancer pain. The treatment gap can be narrowed by educating and training health care workers, and by increasing access to pain relief and palliative care services. However, much of the treatment gap, especially in developing countries, is defined by the inadequate availability and use of pain medications, in particular the opioid analgesics.

Although there are many drug and non-drug pain treatments, the opioid analgesics such as codeine and morphine are *absolutely necessary* for the management of pain due to cancer. When cancer pain is moderate to severe, there is no substitute for opioids in the therapeutic group of morphine. The International Narcotics Control Board (INCB)¹, the international body that monitors, inter alia, global availability of narcotic drugs, emphasizes that these drugs must be available for pain relief.

Opioids are classified as narcotic drugs because they have a potential for abuse. As a consequence, they are regulated by international treaties and national drug control policies. The INCB, the WHO and national governments report that opioids are not sufficiently available for medical purposes. There are a number of reasons, including the low priority for pain management in health care systems, greatly exaggerated fears of addiction, overly restrictive national drug control policies, and problems in procurement, manufacture and distribution of opioids.

In some countries, governments and health care professionals have been working together to improve cancer pain management and palliative care; some have begun to identify and correct overly restrictive regulatory control over the medical use of opioid analgesics. Other countries have yet to address these matters. These Guidelines can be used by governments to determine whether their national drug control policies have established the legal and administrative framework to ensure the medical availability of opioid analgesics, according to international treaties and the recommendations of the INCB and the WHO.

A 1995 INCB report (3) stated:

“...an efficient national drug control regime must involve not only a programme to prevent illicit trafficking and diversion, but also a programme to ensure the adequate availability of narcotic drugs for medical and scientific purposes” (p.14).

¹ The International Narcotics Control Board is an independent treaty-based body that monitors implementation of the Single Convention on Narcotic Drugs, 1954, and other related treaties. For a description of the Board and its activities see: INCB, 1999 (2).

SECTION I PURPOSE AND AUDIENCE

The purpose of these self-assessment Guidelines is to encourage governments to achieve better pain management by identifying and overcoming regulatory barriers to opioid availability.² These Guidelines may also be used to develop balanced national (including state, provincial or territorial authorities where relevant) drug control policies where none already exist. (See Annex 1 for definition of “national policy.”) “Balance” refers to the dual purpose of preventing illegal trafficking and diversion, while ensuring their availability for medical and scientific purposes, in particular for the treatment of pain and suffering (see Section VII for further discussion).

This document is intended for those who make national drug control policy, as well as those who implement it. It may also be used by health care professionals and their organizations to encourage cooperation with governments and to facilitate further education.

This document accomplishes its purpose in several ways:

- I. Background information is presented about the global problem of inadequate cancer pain relief (Section II);
- II. Information is provided about why opioids (i.e., narcotic drugs, opiates³) are needed for the medical management of pain (Section III);
- III. Information is given about the inadequate availability of opioid analgesics in most countries (Section IV);
- IV. The reasons for inadequate availability are given, with specific reference to the overly restrictive regulation of pain medications under some national drug control policies (Section V);
- V. A rationale is presented for governments to assess national policies for balance (Section VI);
- VI. The method that was used to develop guidelines for conducting a self-assessment is described (Section VII);
- VII. The Guidelines are presented to encourage consensus in the adoption of balanced national drug control policy. They are based on international medical and regulatory consensus that national drug control policy should be balanced (Section IX);
- VIII. A checklist of questions is provided to guide the self-assessment (Section X);
- IX. Reference information is provided on page 28-29;
- X. Ordering information for key resources is provided in Annex 2; and
- XI. A directory of the government offices responsible for narcotic regulation (National Competent Authorities) is available from the INCB at the following:

website <http://www.incb.org>

telephone +43-1-26060-4277, facsimile +43-1-26060-5867/5868

² There are three levels of barriers to adequate pain management: economic, medical and regulatory. While these Guidelines focus solely on regulatory issues, it is well understood that economic and medical barriers play major roles in the inadequate treatment of pain. For example, in some countries, for economic reasons, health care professionals are encouraged to use more expensive and less effective pharmaceutical products. This may exacerbate inadequate availability, both for the health care system in general, and for the individual patient. In some countries, scarce medical resources are spent on expensive curative treatments that are futile for patients with late-stage cancer (4). Such policies preclude the provision of palliative care. Finally, medical education that does not address pain management contributes to inadequate pain management.

³ See Annex 1 for an explanation of “opiate” and “opioids,” and other key terms used in this publication.

SECTION X
SELF-ASSESSMENT CHECKLIST

Governments or other interested groups, including health care professionals, may use the following checklist to guide their analysis of national drug control policies. Please note that some inquiry may be needed prior to answering the questions contained on this checklist.

1. Has the government conducted an examination to determine if there are overly restrictive provisions in national (and state, if applicable) drug control policies that impede prescribing, dispensing or needed medical treatment of patients with narcotic drugs, or their availability and distribution for such purposes, and made the necessary adjustments?

- Yes
- No
- Information not available

2. Is there a provision in national drug control policies that recognizes that narcotic drugs are absolutely necessary for the relief of pain and suffering?

- Yes
- No
- Information not available

3. Is there a provision in national drug control policies that establishes that it is the government's obligation to make adequate provision to ensure the availability of narcotic drugs for medical and scientific purposes, including for the relief of pain and suffering?

- Yes
- No
- Information not available

4a. Has the government established administrative authority for implementing the obligation to ensure adequate availability of narcotic drugs for medical and scientific purposes, including licensing, estimates and statistics?¹¹

- Yes
- No
- Information not available

4b. Are adequate personnel (employees) available for the implementation of this responsibility?

- Yes
- No
- Information not available

5a. Does the government have a method to estimate realistically the medical and scientific needs for narcotic drugs, including for the opioid analgesics which are needed for pain relief and palliative care?

- Yes
- No
- Information not available

¹¹ In some cases, the government's policy may be found in either the law or administrative policies, or in both.

5b. Has the government critically examined its method for assessing medical needs for narcotic drugs, as requested by the INCB?

- Yes
- No
- Information not available

5c. Has the government established a satisfactory system to collect information about medical need for opioid analgesics from relevant facilities?

- Yes
- No
- Information not available

6. Does the government furnish annual estimates to the INCB of need for narcotic drugs for the next year in a timely way?

- Yes
- No
- Information not available

7. If it appears that the medical need for opioid analgesics will exceed the estimated amount which has been approved and confirmed by the INCB, is it government policy to furnish a request for a supplementary estimate?

- Yes
- No
- Information not available

8. Does the government submit to the INCB in a timely way the required annual statistical reports respecting production, manufacture, trade, use and stocks of narcotic drugs?

- Yes
- No
- Information not available

9a. Has the government informed health professionals about the legal requirements for the use of narcotic drugs, and provided an opportunity to discuss mutual concerns?

- Yes
- No
- Information not available

9b. Has the government identified and addressed concerns of health care professionals about being investigated for prescribing opioids?

- Yes
- No
- Information not available

10. Is there cooperation between the government and health care professionals to ensure the availability of opioid analgesics for medical and scientific purposes?

- Yes
- No
- Information not available

11. Has the government taken steps, in cooperation with licensees, to ensure that there are no shortages of supply of opioid medications caused by inadequate procurement, manufacture and distribution systems?

- Yes
- No
- Information not available

12. Do national drug control policies provide for the licensing of an adequate number of individuals and entities to support a distribution system that will maximize physical access of patients to pain relief medications?

- Yes
- No
- Information not available

13a. Has the government established a national cancer control programme to which it allocates health care resources?

- Yes
- No
- Information not available

13b. Has the government taken steps to ensure the practice of the WHO Analgesic Method for cancer pain relief by continuing education programmes and by its inclusion in medical, pharmacy and nursing curriculum?

- Yes
- No
- Information not available

14. Is there terminology in national drug control policy that has the potential to confuse the medical use of opioids for pain with drug dependence?

- Yes
- No
- Information not available

15. Are there provisions in national drug control policy that restrict the amount of drug prescribed or the duration of treatment?

- Yes
- No
- Information not available

16. Are there prescription requirements in national drug control policy that may unduly restrict physician and patient access to pain relief?

- Yes
- No
- Information not available

Bibliography

- (1) Selva C. International control of opioids for medical use. *European Journal of Palliative Care*. 1997;4(6):194-198. (Available at <http://www.medsch.wisc.edu/painpolicy/internat/selva.htm>).
- (2) Pain & Policy Studies Group. *Improving Cancer Pain Relief in the World: 2000*. Madison, Wisconsin, USA: University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; 2001. (Available at <http://www.medsch.wisc.edu/painpolicy/publicat/00report/intro.html>).
- (3) Rajagopal MR, Joranson DE, Gilson AM. Medical use, misuse, and diversion of opioids in India. *Lancet*. 2001;358(9276):139-143. (Available through <http://www.medsch.wisc.edu/painpolicy/publicat/01lancet/contents.htm>).
- (4) Colleau SM. Highlights of the INCB report. *Cancer Pain Release*. 1996;9(Suppl):1-4.
- (5) Colleau SM. New World Health Organization opioid guidelines put into action. *Cancer Pain Release*. 2001;14(1).
- (6) MacDonald DM, Finley GA. Governmental barriers to opioid availability in developing countries. *Journal of Pharmaceutical Care in Pain & Symptom Control*. 2001;9(1):5-23.
- (7) Joranson DE, Gilson AM, Jorenby JP. *Availability of opioid analgesics in Asia: Consumption trends, resources, recommendations*. University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; Madison, Wisconsin, USA. Prepared for the 17th Study Programme for Overseas Experts on Drug Abuse and Narcotics Control; Tokyo, Japan; June 26, 2002 (Monograph).
- (8) Joranson DE, Jorenby JP. *Availability of opioid analgesics in Africa and the world*. University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; Madison, Wisconsin, USA. Prepared for the WHO meeting, "A Community Health Approach to Palliative Care for HIV/AIDS and Cancer Patients in Africa"; Gaborone, Botswana; July 9-12, 2002 (Monograph).
- (9) Joranson DE, Ryan KM, Jorenby JP. *Availability of opioid analgesics in Eastern Europe and the world*. University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; Madison, Wisconsin, USA. Prepared for the Workshop on Assuring Availability of Opioid Analgesics for Palliative Care; Budapest, Hungary; February 25-27, 2002 (Monograph).
- (10) Joranson DE, Maurer MA, Jorenby JP. *Disponibilidad de analgésicos opioides en las Américas y en el mundo*. University of Wisconsin Pain & Policy Studies Group/WHO Collaborating Center for Policy and Communications in Cancer Care; Madison, Wisconsin, USA. Preparado para: I Congreso de la Asociación Latinoamericana de Cuidados Paliativos, VII curso Latinoamericano de medicina y cuidados paliativos; Guadalajara, Mexico; 20-22 marzo de 2002 (Monograph).
- (11) International Narcotics Control Board. *Report of the International Narcotics Control Board for 1995: Availability of Opiates for Medical Needs*. New York, NY: United Nations; 1996. (Available through <http://www.incb.org/e/ind ar.htm>).
- (12) World Health Organization. *Achieving Balance in National Opioids Control Policy: Guidelines for Assessment*. Geneva, Switzerland: World Health Organization; 2000. (Available at <http://www.who.int/medicines/library/qsm/who-edm-qsm-2000-4/who-edm-qsm-2000-4.htm>).